News
SBI Investment Portfolio Company EXOSYSTEMS Opens a New Chapter in Sarcopenia Diagnosis
- Media coverage has highlighted how SBI Investment portfolio company EXOSYSTEMS, a specialist in neuromuscular AI digital biomarkers, is bringing innovation to sarcopenia diagnosis, a field that has long relied on gait observation.
- Recognized for technology that can cut clinical trial costs and time by more than 90% using its proprietary Muscle Function Index (MFI), EXOSYSTEMS has been designated an innovative medical device by the Ministry of Food and Drug Safety and has raised a cumulative KRW 15 billion from investors including SBI Investment, NAVER and Daewoong Pharmaceutical.
- Jae Kwang Ahn, CEO of SBI Investment, described EXOSYSTEMS as “a deep tech company with both strong technology and commercialization potential that is expected to grow rapidly,” noting its potential to expand into fields such as rehabilitation and pharmaceutical clinical trials in an aging society.
The full related article is available at the link below.